No Data
Ping An Securities: The supply and demand relationship of active pharmaceutical ingredients continues to improve, and the integration of formulations contributes to long-term growth.
According to IQVIA data, from 2024 to 2028, the global pharmaceutical sales facing patent cliffs and losses are approximately $192 billion, presenting a development opportunity for generic drugs and related specialty active pharmaceutical ingredient companies.
Tonghe Pharmaceutical: Report for the third quarter of 2024
Jiangxi Synergy Pharmaceutical (300636.SZ) released its performance for the first three quarters, with a net income of 95.7365 million yuan, a year-on-year increase of 21.72%.
Jiangxi Synergy Pharmaceutical (300636.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
Jiangxi Synergy Pharmaceutical (300636.SZ): The net income in the third quarter was 26.1844 million yuan, a year-on-year increase of 21.10%.
On October 23, Gelonhui announced the third quarter report for the year 2024, with a revenue of 0.188 billion yuan, a year-on-year increase of 5.61%; the net income attributable to the shareholders of the listed company was 26.1844 million yuan, a year-on-year increase of 21.10%; the net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 25.535 million yuan, a year-on-year increase of 15.94%; the basic earnings per share was 0.0624 yuan.
Jiangxi Synergy Pharmaceutical (300636.SZ): One of the actual controllers, Pang Zhengwei, completed the shareholding of 0.94%.
On October 15th, Gelonhui reported that jiangxi synergy pharmaceutical (300636.SZ) announced that the company recently received a "Notice of Completion of Implementation of Shareholding Reduction Plan" issued by Mr. Pang Zhengwei, one of the controlling shareholders and actual controllers. As of the date of this announcement, Mr. Pang Zhengwei's shareholding reduction plan has been completed, with a reduction of 3.9826 million shares, representing 0.94% of the total shares.
Do Its Financials Have Any Role To Play In Driving Jiangxi Synergy Pharmaceutical Co., Ltd.'s (SZSE:300636) Stock Up Recently?
Risks Still Elevated At These Prices As Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Shares Dive 28%No Data
No Data
